Journal article
The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma
B Thapa, A Salcedo, X Lin, M Walkiewicz, C Murone, M Ameratunga, K Asadi, S Deb, SA Barnett, S Knight, P Mitchell, DN Watkins, PC Boutros, T John
Journal of Thoracic Oncology | ELSEVIER SCIENCE INC | Published : 2017
Abstract
Introduction Results of recent clinical studies of immune checkpoint inhibitors in malignant pleural mesothelioma (MPM) have dampened initial enthusiasm. However, the immune environment and targets of these treatments such as programmed cell death protein 1 and its ligand programmed death ligand 1 (PD-L1) have not been well characterized in MPM. Using a large cohort of patients, we investigated PD-L1 expression, immune infiltrates, and genome-wide copy number status and correlated them to clinicopathological features. Methods Tissue microarrays were constructed and stained with PD-L1(clone E1L3N [Cell Signaling Technology, Danvers, MA]), cluster of differentiation 4, cluster of differentiati..
View full abstractGrants
Awarded by Victorian Cancer Agency
Funding Acknowledgements
This study was supported by the Lyall Watt's Mesothelioma grant awarded by Cancer Council Victoria and Victorian Cancer Agency and in part by research funds from Slater and Gordon, Asbestoswise, and the Operational Infrastructure Support Program provided by the Victorian Government, Australia. Dr. John is the recipient of a National Health and Medical Research Council Early Career Fellowship (APP1074035), and Dr. Thapa is supported by an Australian Postgraduate Award postgraduate scholarship. This study was also supported by the Ontario Institute for Cancer Research to Dr. Boutrous through funding provided by the government of Ontario. Dr. Boutros was also supported by a Terry Fox Research Institute New Investigator Award and a Canadian Institutes of Health Research New Investigator Award. The funding sources had no role in collection, analysis, and interpretation of data or in the writing of the manuscript.